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Abstract
Pseudoxanthoma elasticum (PXE), an autosomal recessive disorder characterized by ectopic 
mineralization, is caused by mutations in the ABCC6 gene. We examined clinically 29 Chinese 
PXE patients from unrelated families, so far the largest cohort of Asian PXE patients. In a subset 
of 22 patients, we sequenced ABCC6 and another candidate gene, ENPP1, followed by 
pathogenicity analyses for each variant. We identified a total of 17 distinct mutations in ABCC6, 
15 of them being previously unreported, including 5 frame-shift and 10 missense variants. In 
addition, a missense mutation in combination with a recurrent nonsense mutation in ENPP1 was 
discovered in a pediatric PXE case. No cases with p.R1141X or del23-29 mutations, common in 
Caucasian patient populations, were identified. The 10 missense mutations in ABCC6 were 
expressed in mouse liver via hydrodynamic tail-vein injections. One mutant protein showed 
cytoplasmic accumulation indicating abnormal subcellular trafficking, while the other nine 
mutants showed correct plasma membrane location. These nine mutations were further 
investigated for their pathogenicity using a recently developed zebrafish mRNA rescue assay. 
Minimal rescue of the morpholino-induced phenotype was achieved with 8 of the 9 mutant human 
ABCC6 mRNAs tested, implying pathogenicity. This study demonstrates that the Chinese PXE 
population harbors unique ABCC6 mutations. These genetic data have implications for allele-
specific therapy currently being developed for PXE.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE), the prototype of heritable ectopic mineralization 
disorders, is characterized by late-onset, yet progressive, calcium hydroxyapatite deposition 
on elastic structures in peripheral connective tissues (Neldner, 1988; Uitto et al., 2010). 
Clinically, PXE manifests with characteristic cutaneous, ocular and cardiovascular findings. 
The disease is inherited in an autosomal recessive manner with apparently complete 
penetrance, and ABCC6 has been identified as the gene harboring mutations in most patients 
with PXE (Bergen et al., 2000; Le Saux et al., 2000; Ringpfeil et al., 2000; Struk et al., 
2000). This gene encodes ABCC6, a putative transmembrane efflux transporter protein 
primarily expressed in the baso-lateral plasma membranes of hepatocytes and to a lesser 
extent in the proximal tubules of the kidneys.
In addition to ABCC6, recent studies have disclosed mutations in the ENPP1 gene in some 
patients with PXE-like cutaneous findings, often associated with extensive vascular 
mineralization (Kalah et al., 2012; Li et al., 2012). ENPP1 mutations also underlie a severe 
ectopic mineralization disorder, generalized arterial calcification of infancy (GACI), an 
autosomal recessive disease, which affects primarily the arterial blood vessels (Ruf et al., 
2005; Rutsch et al., 2003). This disease is commonly diagnosed by pre- or perinatal 
ultrasound, and the affected individuals in most cases die within the first year of life from 
cardiovascular complications. While most cases of GACI are caused by mutations in the 
ENPP1, ABCC6 mutations have also been demonstrated in some patients (Li et al., 2014; 
Nitschke et al., 2012). Thus, there is considerable phenotypic and genotypic overlap 
between PXE and GACI (Li and Uitto, 2013; Nitschke and Rutsch, 2012).
Over 300 distinct mutations in the ABCC6 gene have been identified in patients with PXE, 
two common recurrent mutations, p.R1141X and genomic deletion of exons 23 through 29 
(c.2996-1724_4209-478del; referred to as del23-29), representing 18.5 and 9.9% of all 
reported mutant alleles, respectively (Pfendner et al., 2007; Terry and Hefferson, 2013; 
Uitto et al., 2013). However, essentially all published studies have focused on PXE in 
Caucasian patient populations, and very few mutations have been reported in patients of 
Asian ancestry. In this study, we have investigated a cohort of 29 Chinese PXE patients 
from unrelated families, so far the largest cohort of Asian PXE patients. Genetic analysis of 
22 patients revealed a mutation profile clearly distinct from that found in Caucasian patients, 
and the Chinese PXE patients harbor unique mutations.
RESULTS
Identification of ABCC6 Mutations
A cohort of 29 Chinese patients with PXE was examined, and the diagnosis was initially 
suggested by characteristic cutaneous lesions and histopathology using routine 
Hematoxylin-Eosin as well as Verhoeff van Gieson and von Kossa stains for elastic 
structures and mineralization, respectively (Uitto et al., 2014) (Fig. S1). The majority of 
patients were females (26/29), most of them had the onset at less than 30 years of age, and 
the majority of patients (~90%) had the disease for over 6 years since diagnosis at the time 
of the study (Table S1).
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In a subset of 22 patients, DNA, isolated from either peripheral blood leukocytes or paraffin-
embedded skin biopsies, was available and subjected to mutation analysis first using a 
strategy and primers that we have previously developed for streamlined mutation detection 
in the ABCC6 gene (LaRusso et al., 2010; Pfendner et al., 2007). A total of 36 sequence 
variants in ABCC6 were discovered. These variants included 6 small insertion or deletion 
mutations resulting in premature termination codon (PTC), and these variants were 
considered pathogenic (Fig. 1A). Among the 30 single nucleotide substitutions, we 
identified 7 synonymous mutations while 23 were missense mutations. Among the 
nonsynonymous substitutions, 9 were present in the single nucleotide polymorphism (SNP) 
database (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?
geneId=368&ctg=NT_010393.16&mrna=NM_001171.5&prot=NP_001162.4&orien=forwa
rd) in frequency >1% and were therefore considered to be nonpathogenic polymorphisms. 
Among the 14 amino acid substitutions not present in the SNP database, one of them, c.
3341G>A, has been previously reported as a pathogenic mutation. The remaining 13 amino 
acid substitutions were examined for potential pathogenicity by PolyPhen-2 and SIFT 
prediction programs (Table 1), and 10 putative missense variants were examined for 
subcellular localization in mouse hepatocyte plasma membrane targeting assay and for 
functional pathogenicity in zebrafish mRNA rescue assay in vivo (see below). Among the 
putative pathogenic mutations, only two of them, one missense and one single-nucleotide 
deletion mutation, have been published previously. Most notably, none of the Chinese PXE 
patients had the recurrent p.R1141X or del23-29 mutation. When examined individually, 13 
patients were homozygous or compound heterozygous with mutations in both alleles of 
ABCC6, while in 7 patients only one mutation was found. In the latter cases, search for 
ENPP1 mutations was unyielding.
Assay of membrane targeting of the mutant protein
Among the discovered sequence variants, 13 of them resulted in amino acid substitution 
(Table 1 and Fig. 1B), and they all were initially considered pathogenic because searches of 
the SNP database did not report the presence of these variants or they were present in 
frequency of less than 1%. Analysis of the potential functional consequences of these 
mutations at the protein level by SIFT and PolyPhen-2 bioinformatics programs predicted 
that 6 of them were definitely damaging/probably disruptive while the remaining 7 were 
tolerated or benign (Table 1). In the latter group, three variants, even though not present in 
the SNP database, were recurrent in the Chinese families with PXE in high frequency, and 
they were considered nonpathogenic and not studied further.
Theoretically, missense mutations could inactivate the ABCC6 activity by a number of 
mechanisms. First, it is possible that the mutant protein is mis-localized within the 
hepatocytes and does not migrate into the appropriate plasma membrane location on the 
baso-lateral surface of hepatocytes (Aranyi et al., 2013). Alternatively, the protein is 
appropriately targeted to the correct membrane location but the transporter activity is 
compromised by inability of the protein to perform its transport function, for example due to 
deficient binding and hydrolysis of ATP (Ilias et al., 2002). We first determined the 
subcellular localization of the human mutant protein expressed from an expression vector 
under the control of a liver-specific mouse albumin promoter delivered to the mouse liver by 
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hydrodynamic injection through the tail vein (Jiang et al., 2010). After 3 days of delivery, 
the livers were harvested, and the subcellular localization of the human as well as 
endogenous mouse ABCC6 protein was determined by immuno staining with antibodies that 
differentially recognize human and mouse protein epitopes (Fig. 2). As demonstrated 
previously, the endogenous mouse ABCC6 protein resides at the baso-lateral surface of the 
hepatocyte plasma membrane (Pomozi et al., 2013). Similarly, 9 out of the 10 human mutant 
proteins tested in this study were co-localized with the mouse protein at the proper 
membrane location (Fig. 2A). However, one mutation, p.L605P, did not allow the protein to 
migrate to the plasma membrane, and the mutant protein was localized exclusively in the 
cytoplasm (Fig. 2A and B). Similarly, another, previously identified mutation, p.R1114P, 
resulted in partial retention of the protein in the cytoplasm while some cells demonstrated 
plasma membrane staining (Aranyi et al., 2013) (Fig. 2B).
A chaperone compound, 4-phenylbutyrate (4-PBA), has previously been shown to facilitate 
transfer of some mutant mis-targeted ABCC6 molecules from the cytoplasm to the plasma 
membrane (Aranyi et al., 2013). Consequently, we tested the effect of 4-PBA on the 
subcellular localization of the p.L605P and p.R1114P mutants by treating mice with this 
compound two days prior and four days following the injection of the expression construct 
for a total of 6 days. 4-PBA clearly facilitated the transfer of the cytoplasmic mutant 
p.R1114P protein to the plasma membrane, as shown previously (Pomozi et al., 2014) (Fig. 
2B). However, this compound had no effect on the subcellular localization of the protein 
harboring the mutation p.L605P. Thus, 4-PBA may be of help in facilitating the proper 
targeting of some, but not all, mutant ABCC6 proteins to the plasma membrane.
Demonstration of pathogenicity in zebrafish mRNA rescue assay
The pathogenicity of the missense mutations identified in ABCC6 was further investigated in 
a zebrafish mRNA rescue assay that we have recently developed (Li et al., 2010a; Zhou et 
al., 2013). In this assay, zebrafish embryos are injected with an abcc6a morpholino which 
causes knock-down of the corresponding gene expression. As a consequence, the zebrafish 
embryos develop a profound phenotype consisting of pericardiac edema, stunted growth and 
curled tail, and the developing embryos die before the age of 7 days post fertilization (dpf) 
(Fig. 3). This phenotype can be fully rescued by injection of wild-type human ABCC6 
mRNA together with the morpholino (Fig. 3). We consequently injected zebrafish embryos 
with the morpholino together with human ABCC6 mRNA harboring missense mutations 
identified in this study. As a negative control, the morpholino was injected with the human 
mRNA harboring stop codon mutation p.R1141X. As shown in Fig. 3, this mRNA 
containing the nonsense mutation did not rescue the phenotype. Injection of mutant mRNAs 
harboring the missense mutations identified in this study together with the morpholino 
revealed that 8 out of 9 mutations tested did not provide significant rescue as judged by 
either morphology of the zebrafish embryos (Fig. 3) or by the percent of lethality (Table 2) 
at 4 dpf, suggesting that they are pathogenic. Only one mutant mRNA, p.R64Q, resulted in 
rescue comparable to that of the wild-type mRNA (Fig. 3 and Table 2). However, the 
corresponding mutation, c.191G→A, was not present in the SNP database, and it is unclear 
whether this is a pathogenic mutation in the 5 patients with PXE.
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Identification of mutations in the ENPP1 gene
A male patient diagnosed as having PXE by the presence of characteristic cutaneous 
findings and histopathology of the skin did not reveal the presence of mutations in ABCC6 
(Fig. 4). Careful examination of the patient revealed several unusual features. First, the 
patient’s cutaneous findings had been noted definitely to be present as early as at 8 years of 
age categorizing him with a diagnosis of pediatric PXE. Furthermore, in addition to 
characteristic yellowish papules in the axillary fossa, the patient had large areas of 
hyperpigmented lesions on the trunk, a finding not characteristic of PXE (Fig. 4A). With the 
notion that mutations have been recently disclosed in the ENPP1 gene in patients with 
cutaneous PXE-like lesions (Kalah et al., 2012; Li et al., 2012), we next sequenced ENPP1, 
which identified 2 heterozygous mutations, p.Y261X and p.S479F, and the parents were 
heterozygous carriers, respectively (Fig. 4B and D). The nonsense mutation, p.Y261X, has 
been previously reported (Ruf et al., 2005). Sequence alignments indicated that serine at the 
amino acid position 479 is highly conserved during evolution (Fig. 4C). This sequence 
variant, p.S479F, was not present in the SNP database, and this mutation was predicted to be 
probably damaging (0.99) and damaging (0), when analyzed by PolyPhen-2 and SIFT 
programs, respectively. Collectively, the mutation analysis in the Chinese cohort of PXE 
demonstrated considerable genetic heterogeneity and identified a number of mutations not 
previously reported in the literature.
DISCUSSION
Understanding of the mechanisms leading to aberrant mineralization of connective tissues 
has been advanced by observations on a group of heritable disorders manifesting with 
ectopic mineralization. The prototype of such conditions is PXE, an autosomal recessive 
disorder which affects a number of organs by ectopic mineralization, with primary clinical 
findings in the skin, the eyes, and the cardiovascular system (Neldner, 1988; Uitto et al., 
2010). PXE is a rare disorder, with an estimated prevalence of ~1:50,000 which would 
imply that there are ~7,000 to 8,000 affected individuals in the United States, and with the 
same prevalence as many as 50,000 patients in China. The diagnosis of PXE is made by a 
combination of clinical findings in the skin and the eyes, supported by histopathologic and 
molecular diagnostic observations (Uitto et al., 2014). While the manifestations of PXE are 
of late onset and the disease progresses slowly, PXE is associated with major clinical 
complications, including loss of central vision often leading to blindness, and occurrence of 
catastrophic cardiovascular events, including early myocardial infarcts and strokes. There is 
a considerable spectrum of phenotypic presentations and severity of the disease: At one end 
of the spectrum, young patients in their infancy, with considerable vascular involvement, 
have been diagnosed with PXE-like cutaneous findings, often classified as pediatric PXE (Li 
et al., 2013; Li et al., 2014). In addition, patients with GACI, typically caused by mutations 
in the ENPP1 gene, can demonstrate PXE-like findings, supporting the notion that there is 
considerable both clinical and genetic overlap between PXE and GACI (Nitschke and 
Rutsch, 2012).
The classic form of PXE is caused by mutations in the ABCC6 gene, and over 300 distinct 
mutations have been identified representing well over 1,000 mutant alleles (Terry and 
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Hefferson, 2013). Among the published mutations, two common recurrent mutations, 
p.R1141X and del23-29, account for up to 30% of all mutant alleles (Pfendner et al., 2007; 
Terry and Hefferson, 2013). Examination of the ancestry and geographic distribution of 
patients in the ABCC6 mutation databases reveals that most patients tested are apparently 
Caucasians from the United States or European countries, and specific reports of mutations 
in the Italian, French and German cohorts have been published (Chassaing et al., 2007; 
Gheduzzi et al., 2004; Pfendner et al., 2007; Schulz et al., 2006). Examination of the 
mutation database indicates that the frequent p.R1141X mutation is distributed widely 
across Europe, while deletion of exons 23-29 (del23-29) is encountered in Northern Europe 
and in Northern Mediterranean countries (LaRusso et al., 2010). In addition, limited 
numbers of patients, with specific mutations, have been reported from Greece, Turkey, 
South Africa and Brazil (Akoglu et al., 2014; Faria et al., 2013; LaRusso et al., 2010; Le 
Saux et al., 2002; Ramsay et al., 2009). There is a striking paucity of mutation reports on 
individuals of Asian ancestry. Specifically, there are only four distinct mutations reported in 
Japanese patients with PXE, and in addition, six ABCC6 sequence variants have been 
identified as a cause of angioid streaks in Japanese patients, an eye finding often associated 
with PXE (Noji et al., 2004; Sato et al., 2009; Tanioka et al., 2014; Yoshida et al., 2005). 
There is only one ABCC6 mutation reported in a Chinese patient with PXE (Yang et al., 
2008).
In the present study, we have clinically examined a cohort of 29 Chinese patients with PXE, 
and DNA was available to specifically sequence the exons and flanking intronic sequences 
of ABCC6 in a subset of 22 patients. Among the 36 sequence variants identified in ABCC6, 
six small insertions or deletions were causing PTCs, five of them being previously 
unreported. Among the 23 nonsynonymous missense mutations, ten were initially 
considered potentially pathogenic based on their absence or presence in low frequency 
(<1%) in SNP database, and as judged by bioinformatics prediction programs PolyPhen-2 
and SIFT to be damaging to the protein function. Among the 10 putative pathogenic 
missense mutations tested in zebrafish mRNA rescue assay, nine of them did not provide 
rescue, confirming the pathogenic nature of the amino acid substitutions. Only one of the 
mutant mRNAs, harboring mutation p.R64Q, was able to rescue the zebrafish phenotype, 
similar to that of wild-type mRNA. However, this mutation was not present in the SNP 
database and three of the five patients with this sequence variant had another allelic ABCC6 
mutation. Therefore, it is unclear whether this mutation, p.R64Q, is pathogenic or not. It 
should be noted that no ABCC6 or ENPP1 mutations were found in two patients, and the 
overall rate of detection of mutations in ABCC6 and ENPP1 was 80 percent (35 mutant 
alleles of a total 44). It should be noted that, the mutation detection strategy utilized PCR 
amplification of individual exons and flanking intronic sequences. This approach does not 
detect mutations in the regulatory upstream sequences or in the 3′-UTR, deeper intronic 
sequences, or large insertions or deletions (Pfendner et al., 2007).
The consequences of missense mutations were also tested in vivo in a mouse system which 
examines the subcellular targeting of the mutant protein in mouse hepatocytes following 
hydrodynamic delivery of an expression vectors through the tail vein. The wild-type ABCC6 
protein localizes to the basolateral surface of hepatocytes, and 9 out of 10 tested missense 
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mutations allowed the protein to target the physiological plasma membrane location. Only 
one mutation, p.L605P, resulted in cytoplasmic localization of the mutant protein. 
Previously, the mutant protein harboring p.R1114P mutation has been shown to remain in 
cytoplasmic localization which could be corrected by treatment with 4-PBA, a chaperone 
molecule. However, treatment of mice expressing miss-targeted protein with p.L605P 
mutation did not result from correction of the subcellular localization. Thus, 4-PBA 
treatment may be applicable for correction of the subcellular localization only to selected 
mutant ABCC6 proteins with missense mutations.
One of the patients was diagnosed as PXE manifested with somewhat unusual features, 
including relatively early age at onset and presence of atypical cutaneous findings, such as 
extensive hyperpigmentation on the trunk, not a characteristic feature of PXE. Analysis of 
the ABCC6 gene failed to identify mutations, but subsequent sequencing of the ENPP1, 
typically associated with GACI, revealed the presence of a nonsense mutation, p.Y261X, 
and a heterozygous missense mutation, p.S479F. The latter mutation is pathogenic, based on 
its absence from the SNP database, conservation of the serine-479 through evolution from 
zebrafish to human, and prediction by PolyPhen-2 and SIFT programs as damaging. This 
previously unreported missense mutation contributes to the growing database of ENPP1 
mutations, and this case also illustrates the phenotypic overlap between PXE and GACI. It 
should be noted that mutations in the ENPP1 gene have been recently identified in Cole 
disease, a rare autosomal dominant genodermatosis featuring punctate keratoderma, patchy 
hypopigmentation, and uncommonly, cutaneous calcifications (Eytan et al., 2013). These 
observations may have relevance to pigmentary changes noted in our patient diagnosed with 
pediatric PXE.
Collectively, this study identified 16 mutations, 15 of them in ABCC6 and 1 in ENPP1, in 
the Chinese PXE population, with implications for accurate diagnosis and subclassification. 
This information can be used for genetic counseling, and it forms the basis for prenatal 
testing and preimplantation genetic diagnosis in future pregnancies in families at risk for 
recurrence. Knowledge of the specific mutations can also be used for presymptomatic 
testing in families with known history of PXE (Akoglu et al., 2014; Li et al., 2010b). 
Important for the patients, identification of the precise nature of the mutations underlying 
the PXE phenotype provides a basis for development of treatment modalities tailored to be 
allele specific.
MATERIAL AND METHODS
Patient samples
A total of 29 unrelated patients with the putative diagnosis of PXE were investigated. 
Informed consent was obtained from all subjects, and the present study was approved by the 
local Medical Research Ethics Committee at Xijing Hospital, Fourth Military Medical 
University, Xi’an, China. The primary diagnosis of PXE was based on dermatological, 
ophthalmologic, and/or histopathologic evaluations (Uitto et al., 2014). In each proband, the 
skin lesions were histologically confirmed to be consistent with the diagnosis of PXE by the 
observation of calcified elastic fibers in biopsy specimens upon hematoxylin and eosin, 
Verhoeff van Gieson and/or von Kossa stains with standard protocols.
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Mutation analysis
Genomic DNA was isolated from peripheral blood leukocytes or paraffin embedded skin 
tissues from 22 patients from whom samples were available, according to standard 
procedures. Mutation detection comprised polymerase chain reaction (PCR) amplification of 
each of the 31 exons in the ABCC6 gene using primer pairs placed on the flanking intronic 
sequences (Pfendner et al., 2007). This protocol excludes amplification of the two ABCC6 
pseudogenes with sequences corresponding to the 5′end of ABCC6 (Pulkkinen et al., 2001). 
Purified PCR products were sequenced for variants by comparison with the published cDNA 
sequence (Gen Bank accession no. NM_001171). The samples in which no mutations were 
found in the ABCC6 gene were further analyzed for the ENPP1 gene using the same 
strategy. Evolutionary conservation of the amino acid residue serine-479 in ENPP1 was 
examined by sequence alignment with Ensemble program.
Mice
Immunodeficient Rag1−/− mice in C57/BL6 background (strain: 002216F; Jackson Labs, 
Bar Harbor, ME), which are wild-type for Abcc6, were used in this study. The mice were 
maintained under standard laboratory conditions and were handled in accordance with the 
guidelines for animal experiments by the Institutional Animal Care and Use Committee of 
Thomas Jefferson University.
Reagents, plasmid and site-directed mutagenesis
Sodium 4-phenylbutyrate (4-PBA) was purchased from Sigma-Aldrich (Deisenhofen, 
Germany) and dissolved in 0.9% NaCl prior to use. A full-length wild-type human ABCC6 
cDNA was cloned into pLIVE™ expression vector purchased from Mirus (MIR5420, 
Madison, WI). Using this cDNA as a template, ten different ABCC6 missense DNA-
constructs were obtained by site-directed mutagenesis following the manufacturer’s 
instructions (Agilent, Santa Clara, CA).
Liver-specific expression of ABCC6 variants in mice
Liver-specific expression of ABCC6 variants was performed in mice as described in our 
previous studies (Jiang et al., 2010; Jiang et al., 2006; Pomozi et al., 2014) Briefly, pLIVE 
expression vector (Mirus Bio, Madison, WI) containing the wild-type or mutant ABCC6 was 
delivered into the mice by hydrodynamic tail-vein injection of 10% body volume of 
TransIT-QR hydrodynamic delivery solution (Mirus), as recommended by the 
manufacturer’s instructions, using a 26-gauge syringe needle. At least three mice were 
injected with each form of the human ABCC6 cDNA. Mice were sacrificed 3–4 days after 
hydrodynamic tail vein injections and the livers were harvested for immunofluorescence.
4-PBA treatment of mice
Mice received intraperitoneal injection of 4-PBA (100 mg/kg per day), once a day for 4 days 
initiated at the time of hydrodynamic tail-vein injection, and they additionally received an 
approximate dosage of 1000 mg/kg per day in the drinking water, two days prior and four 
days following the injection, for a total of 6 days.
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Immunofluorescence
Immunofluorescence was performed on 8-μm thick frozen liver sections. Slices were fixed 
in methanol and then washed with PBS. After incubation in blocking buffer for 13hour, the 
primary antibody recognizing human ABCC6 protein (M6II-7, 1:100; abcam, Cambridge, 
MA) was added first for 1 hour, followed by incubation with the primary antibody specific 
for mouse ABCC6 protein (s-20, 1:200; Santa Cruz, Dallas, Texas) for 13hour. After 
washing with PBS, the sections were incubated with secondary antibodies for 1 hour and the 
nuclei were stained with 4′, 6-diamidino-2-phenylindole for 53minutes. The stained samples 
were analyzed using a fluorescent microscope (Zeiss, Göttingen, Germany).
Zebrafish mRNA rescue assay
To test the potential pathogenicity of ABCC6 missense mutations, a zebrafish mRNA rescue 
assay was performed as described previously (Li et al., 2010a; Zhou et al., 2013). Briefly, 
human ABCC6 variants were cloned in Bluescript II SK- vector, and mRNA was generated 
by in vitro transcription using the mMessage mMachine kit (Ambion, Austin, TX). A 
morpholino specific for zebrafish abcc6a sequence was injected into one- to four-cell-stage 
embryos either alone or in combination with the human, either mutant or wild-type ABCC6 
mRNA (2.4 mmol). The injected zebrafish embryos were followed for their phenotype and 
survival rate on daily intervals.
Ethics Statement
Informed written consent was obtained from all subjects, and the present study was 
approved by the local Medical Research Ethics Committee at Xijing Hospital, Fourth 
Military Medical University, Xi’an, China.
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Use Committee of Thomas Jefferson University.
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Figure 1. The positions of ABCC6 mutations identified in Chinese patients with PXE
(a) Intron-exon organization of ABCC6 gene. Vertical boxes represent the 31 exons; 
Missense mutations are shown above, and insertion or deletion mutations resulting in PTC 
below the line; Green exons code for the two nucleotide-binding fold domains of the 
protein; Black, previously reported mutations; Red, to our knowledge previously unreported 
mutations; *denotes the presence of the mutation in multiple alleles/patients with the 
number of affected alleles in parenthesis. (b) Positions of the missense variants in the 
membrane topology model of the ABCC6 protein. The various protein domains are 
delineated by horizontal arrows above; the positions of amino acid variants investigated in 
the study are in red; nucleotide binding fold domains and intracellular loops are colored with 
gray and blue, respectively.
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Figure 2. Subcellular localization of human ABCC6 missense variants expressed in mouse liver, 
and the effect of 4-phenylbutyrate (4-PBA) on their localization
(a) The human (red) and mouse (green) ABCC6 proteins were detected on frozen sections of 
mouse liver by immunofluorescence with species specific primary antibodies three days 
after hydrodynamic tail vein injection of each ABCC6 missense variant in an expression 
vector. (b) Mice injected with ABCC6 missense variants were treated with (b, right panels) 
or without (b, left panels) 4-PBA. Scale bar = 100 mm.
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Figure 3. Morphology of zebrafish 4 days after co-injection of an ABCC6A knock-down 
morpholino together with different human ABCC6 mRNA variants
The morpholino-induced phenotype consisting of pericardiac edema, stunted growth and 
curled tail, similar to zebrafish injected with morpholino (MO) alone, was observed in 
zebrafish co-injected with human ABCC6 mRNA carrying p.R1141X, p.P4H, p.A9E, 
p.P21S, p.R419Q, p.E125K, p.E709G or p.L948P mutation, indicating lack of rescue and 
implying pathogenicity. Zebrafish co-injected with MO and ABCC6 mRNA carrying R64Q 
mutation showed wild-type phenotype, similar to fish injected with MO together with 
human wild-type (WT) ABCC6 mRNA.
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Figure 4. Cutaneous presentation, histopathology and mutation detection in a pediatric patient 
with PXE
(a) Hyperpigmentation on the trunk (left) and yellowish papules in the axillary fossa (upper 
right); Aberrant calcification in the dermis detected by von Kossa stain (bottom right); (b) A 
heterozygous mutation, p.S479F, in the ENPP1 gene revealed by mutation analysis (arrow); 
(c) Conservation of the serine-479 during evolution from zebrafish to human (outlined). 
Scale bar = 100 mm.
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Table 1
The missense variants of ABCC6 discovered in 22 Chinese patients with PXE, and bioinformatics predictions 
of the consequence of the mutations
Mutations SIFT+ PolyPhen2+
At DNA level* At protein level
c.1814T>C p.Leu605Pro Damaging (0) Probably (1)
c.373G>A p.Glu125Lys Damaging (0.01) Probably (0.997)
c.11C>A p.Pro4His Damaging (0) Probably (0.957)
c.1256G>A p.Arg419Gln Damaging (0) Probably (0.994)
c.2843T>C p.Leu948Pro Damaging (0) Probably (0.988)
c.2126A>G p. Glu709Gly Damaging (0) Probably (0.916)
c.2501T>C p.Met834Thr Tolerated (0.28) Benign (0.047)
c.61C>T p.pro21Ser Tolerated (0.45) Benign (0.209)
c.191G>A p.Arg64Gin Tolerated (0.21) Benign (0.051)
c.26C>A p.Ala9Glu Damaging (0.02) Benign (0.109)
c.268G>A p.Ala90Thr Tolerated (0.5) Benign (0)
c.232G>A (x7) p.Ala78Thr Tolerated (0.18) Benign (0.018)
c.4324G>A (x2) p.Arg1442Thr Tolerated (0.47) Benign (0.188)
*
The recurrent mutation in multiple alleles is indicated with the number of affected alleles in parentheses.
+
Indicates the prediction of the consequences of the mutations on the protein function with the score in parentheses.
J Invest Dermatol. Author manuscript; available in PMC 2015 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Jin et al. Page 18
Table 2
Zebrafish mRNA rescue assay
Group* ABCC6 mRNA variant No. of embryos injected Lethality (%)†
No injection - 192 8.7
MO alone - 68 79.3
MO+ p.R1141X 163 73.8
MO+ WT 80 23.4
MO+ p.P4H 71 85.9
MO+ p.A9E 94 83.0
MO+ p.P21S 93 79.0
MO+ p.R64Q 83 28.7
MO+ p.E125K 109 63.2
MO+ p.R419Q 48 89.1
MO+ p.E709G 64 65.6
MO+ p.M834T 118 64.4
MO+ p.L948P 109 71.1
*
Zebrafish embryos were injected at day 0 with an abcc6a morpholino (MO) alone or with human ABCC6 mRNA, either wild-type (WT) or 
harboring different mutations.
†
The cumulative number of dead embryos at 4 days after injection, expressed as % of the total number of embryos injected.
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